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Background: Evidence from cachectic cancer patients and animal models of cancer cachexia supports the
involvement of Forkhead box O (FoxO) transcription factors in driving cancer-induced skeletal muscle wasting.
However, the genome-wide gene networks and associated biological processes regulated by FoxO during cancer
cachexia are unknown. We hypothesize that FoxO is a central upstream regulator of diverse gene networks in
skeletal muscle during cancer that may act coordinately to promote the wasting phenotype.
Methods: To inhibit endogenous FoxO DNA-binding, we transduced limb and diaphragm muscles of mice with
AAV9 containing the cDNA for a dominant negative (d.n.) FoxO protein (or GFP control). The d.n.FoxO construct
consists of only the FoxO3a DNA-binding domain that is highly homologous to that of FoxO1 and FoxO4, and
which outcompetes and blocks endogenous FoxO DNA binding. Mice were subsequently inoculated with Colon-26
(C26) cells and muscles harvested 26 days later.
Results: Blocking FoxO prevented C26-induced muscle fiber atrophy of both locomotor muscles and the diaphragm
and significantly spared force deficits. This sparing of muscle size and function was associated with the differential
regulation of 543 transcripts (out of 2,093) which changed in response to C26. Bioinformatics analysis of upregulated
gene transcripts that required FoxO revealed enrichment of the proteasome, AP-1 and IL-6 pathways, and included
several atrophy-related transcription factors, including Stat3, Fos, and Cebpb. FoxO was also necessary for the
cancer-induced downregulation of several gene transcripts that were enriched for extracellular matrix and sarcomere
protein-encoding genes. We validated these findings in limb muscles and the diaphragm through qRT-PCR, and further
demonstrate that FoxO1 and/or FoxO3a are sufficient to increase Stat3, Fos, Cebpb, and the C/EBPβ target gene, Ubr2.
Analysis of the Cebpb proximal promoter revealed two bona fide FoxO binding elements, which we further establish are
necessary for Cebpb promoter activation in response to IL-6, a predominant cytokine in the C26 cancer model.
Conclusions: These findings provide new evidence that FoxO-dependent transcription is a central node controlling
diverse gene networks in skeletal muscle during cancer cachexia, and identifies novel candidate genes and networks
for further investigation as causative factors in cancer-induced wasting.
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Cachexia is a devastating condition that affects up to
80% of patients with cancer, particularly those with can-
cers of the lung and upper GI tract [1]. The condition is
characterized by progressive weight loss due to signifi-
cant skeletal muscle wasting, in the presence or absence
of adipose tissue wasting. Importantly, the muscle wast-
ing causes significant muscle weakness that negatively
affects physical function and independence, and thus
quality of life. In addition, muscle and body wasting dur-
ing cancer is also associated with a reduced tolerance to
chemotherapy [2], increased complications from surgical
and radiotherapeutic treatments [3], higher rate of meta-
static disease and decreased survival [4]. Therefore, de-
veloping treatment strategies to deter cancer cachexia is
critically important to enhancing the quality of life and
survival of cancer patients. However, in order for this to
happen, a better understanding of the mechanisms which
drive muscle wasting during cancer is needed.
Skeletal muscle wasting during cancer displays marked
similarities to other atrophy-inducing conditions, in that the
loss of muscle mass is characterized by increased protein
degradation and decreased protein synthesis [1,5]. However,
recent studies demonstrate that muscle wasting during can-
cer is also related to disruptions in the dystrophin glycopro-
tein complex and muscle fiber integrity and impaired
myogenic capacity [6,7], thus emphasizing the unique and
complex nature of cancer cachexia. The upstream mole-
cules implicated in driving these muscle pathologies during
cancer include several pro-inflammatory cytokines that are
increased in the circulation of cancer patients and tumor-
bearing mice [1,8]. Intrinsic to the muscle, mechanistic evi-
dence demonstrates the requirement of inhibitor of kappa
B kinase beta (IKKβ) activation and the subsequent degrad-
ation of the inhibitor of kappa B alpha (IκBα) [7,9,10] for
cancer-induced muscle atrophy and myogenic impairment.
Also required for the atrophy phenotype during cancer are
the transcription factors, Signal Transducer and Activator
of Transcription 3 (STAT3), which acts downstream of IL-6
[11,12], CCAAT/enhancer-binding protein beta (C/EBPβ),
which is activated by p38 mitogen activated protein kinase
(MAPK) [13], and activator protein-1 (AP-1) [14], which is
activated through extracellular regulated kinase 1 and 2
(ERK 1/2) MAPK [15]. Lastly, evidence from our lab and
another demonstrates that activation of Forkhead BoxO
(FoxO) transcription factors also plays a causative role in
cancer-induced muscle wasting [16,17].
Skeletal muscle expresses three FoxO family members,
including FoxO1, FoxO3 and FoxO4, with both FoxO1 and
FoxO3a significantly upregulated in cachectic muscles from
LLC and C26 tumor-bearing mice [9,16]. Moreover, FoxO1
is also upregulated in skeletal muscle of human cancer pa-
tients, and was recently identified as a cachexia-associated
gene [18]. Importantly, activation of the FoxO transcriptionfactors is both sufficient to cause muscle atrophy and ne-
cessary for muscle wasting in response to numerous cata-
bolic conditions, including cancer cachexia associated with
Lewis Lung Carcinoma [16] and Sarcoma-180 [17]. Thus,
these findings from both human cancer patients and ani-
mal models of cancer cachexia strongly support the in-
volvement of FoxO in driving the muscle atrophy process.
Despite this, the genome-wide gene networks regulated by
FoxO during cancer cachexia are unknown. Indeed, al-
though the FoxO factors are well established to regulate
genes involved in skeletal muscle proteolysis through the
ubiquitin proteasome pathway and autophagy, due to the
complex nature of cancer cachexia, we hypothesize that
FoxO regulates additional gene networks which promote
the wasting phenotype. Indeed, identifying the broader
gene targets regulated by FoxO is an important next step
which may unveil novel insight into the mechanisms which
promote cancer-induced muscle wasting.
The purpose of the current study was to determine the
requirement of FoxO for locomotor muscle and diaphragm
muscle wasting and weakness in response to Colon-26
(C26) adenocarcinoma, and provide the first genome-wide
analysis of the genes and biological networks targeted by
FoxO in response to C26 tumor burden. We found that
FoxO is necessary for C26-induced muscle wasting of both
locomotor muscles and the diaphragm, and that this was
associated with its regulation of genes involved in not only
proteolysis, but additional atrophy-related transcriptional
pathways, including the IL-6 and AP-1 pathways. In
addition we also identified FoxO as a novel regulator of
gene repression during cancer cachexia, with the most
enriched gene networks related to the structure and func-
tional integrity of the extracellular matrix and muscle
sarcomere. The data presented in this study thus highlights
novel candidate genes and biological networks that are reg-
ulated downstream of FoxO that may be further explored
as causative factors in cancer-induced muscle wasting.
Methods
Animals
Male CD2F1 mice weighing ~20 g were purchased from
Charles River Laboratories (Wilmington, Massachusetts)
and used for all animal experiments. Mice were maintained
in a temperature and humidity-controlled facility with a
12-h light/dark cycle and water and standard diet were pro-
vided ad libitum. The University of Florida Institutional
Animal Care and Use Committee approved all animal
procedures.
AAV vectors
The d.n.FoxO construct used to inhibit FoxO-dependent
transcription encodes for amino acids 141–266 of hu-
man FoxO3a which encompasses only the FoxO3a DNA
binding domain. The amino acid sequence of the d.n.FoxO
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(aa140-265), 85% sequence identity with mouse FoxO1
and 75% sequence identity with mouse FoxO4 (Figure 1),
all of which share >90% sequence conservation within this
region. Since the d.n.FoxO protein lacks a transactivation
domain, the d.n.FoxO blocks DNA-binding dependent
transcription by the FoxO factors through outcompeting
endogenous FoxO factors for binding to FoxO DNA bind-
ing elements (FBEs) in gene regulatory regions. The d.n.
FoxO is fused to a DsRed protein tag to allow for quantita-
tion of the ectopic protein and has been used and de-
scribed by our lab previously [16,19]. The d.n.FoxO cDNA
was sub-cloned into the SpeI and ClaI sites of pTR-UF12
under the control of a cytomegalovirus and chicken β-
actin hybrid promoter. The pTR-UF12 shuttle vector also
contains the internal ribosome entry site (IRES) that allows
for the bi-cistronic expression of GFP for measurement
of AAV9 transduction efficiency. The pTR-UF12-d.n.FoxO
and pTR-UF12 (empty vector, ev) were packaged in
rAAV9 and titered at the University of Florida Powell
Gene Therapy Center Vector Core Laboratory using previ-
ously published methods [20]. The vectors were purified
by iodixanol gradient centrifugation and anion-exchange
chromatography, as described previously [20] and final for-
mulations of AAV9-d.n.FoxO and AAV9-ev were provided
in lactated Ringer’s solution.
In vivo AAV delivery
Mice were acutely anesthetized with isoflurane gas (5%, in-
duction; 3% maintenance) delivered via a nose cone. ForFigure 1 Transduction of locomotor muscles and the diaphragm with
FoxO protein sequence, which includes amino acids 141–265 of mouse Fo
sequences. FoxO1 shares ~85% amino acid sequence identity and FoxO4 7
denoted in green), all of which share >90% sequence conservation within
Forkhead Domain are highlighted in red and are denoted by hash marks (#
expression of d.n.FoxO (or empty vector), which also contain an IRES drivin
limb compartment of mice to transduce the TA and EDL muscles, or inject
diaphragm. (B) Representative muscle cross-sections showing AAV9 transfe
as visualized via direct GFP fluorescence. (C) Confirmation that the d.n.FoxO
FoxO was confirmed through western blot using an antibody against DsReAAV delivery to the TA and EDL, a small incision was
made on the lateral side of the lower leg and the TA muscle
exposed. Each vector was diluted in lactated Ringer solution
such that 1 × 1011 vector genomes (VG) were injected in
25 μl along the tibia into the TA and EDL muscles, as previ-
ously described by others [21]. For targeting to the dia-
phragm, we performed a single intrathoracic injection of
1 × 1011 vector genomes/mouse in 400 μl of sterile lactate
Ringer’s solution. This minimally invasive technique causes
high and widespread transduction of the diaphragm [22,23].
Plasmid DNA vectors
Expression plasmids for the FoxO1 triple phosphoryl-
ation mutant (Addgene Plasmid 17547, deposited by Dr.
Domenico Accili) and the FoxO3a triple phosphorylation
mutant (Addgene Plasmid 10711, deposited by Dr. William
Sellers ), have been described previously [24] and were
injected and electroporated into mouse TA muscles as
described by us previously [16]. The pGL4.20 luciferase
reporter plasmids containing either a wildtype Cebpb pro-
moter fragment (−516 to −1) or a mutated version which
is mutated at both FoxO binding elements (FBE1 (−234
to −225) and FBE2 (−208 to −199)) were generous gifts
from Dr. Akiyoshi Fukamizu, and have been described
previously [25]. The pRL-TK-Renilla luciferase reporter
plasmid was purchased from Promega (Madison, WI).
Cancer cachexia
Murine C26 cells were obtained from the National Cancer
Institute Tumor Repository (Frederick, MD, USA) andAAV9-d.n.FoxO. (A) Alignment of the dominant negative (d.n.)
xO3a, with the corresponding mouse FoxO1 and FoxO4 amino acid
5% sequence identity with the d.n.FoxO protein (shared amino acids
this region. The 6 amino acid residues involved in DNA binding of the
) above the aligned sequences. (B and C) The AAV9 vectors driving
g the expression of GFP, were injected directly into the anterior hind
ed directly into the intrathoracic cavity of mice to transduce the
ction efficiency in the TA, EDL and diaphragm ~26 days post-injection
protein was also expressed in muscles transduced with AAV9-d.n.
d, which is fused to the d.n.FoxO protein.
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was induced in mice by injecting 5×105 C26 cells (or 1×
PBS as control) subcutaneously into each flank on the
same day as AAV delivery. Muscles were harvested when
the largest tumor diameter reached 1.5 cm (~26 days
post-inoculation) when mice had lost ~15% of tumor-free
body weight.
Histochemistry
Transduction efficiency of AAV9 was determined in 10 μm
cross-sections via direct visualization of GFP fluorescence
using a Leica DM5000B microscope (Leica Microsystems,
Wetzlar, Germany) prior to and/or following fixation with
4% paraformaldehyde and labeling of muscle fiber borders
with Alexa Fluor-conjugated wheat germ agglutinin (Invi-
trogen) for 1 hr. Leica application suite, version 3.5.0 soft-
ware was used to trace and measure fiber CSA as described
previously [27].
In vitro muscle contractile properties
The solutions and methods used for measurements of
muscle isometric function in EDL muscles were de-
scribed in detail previously [27,28].
C2C12 cell culture and IL-6 treatment
Mouse C2C12 skeletal myoblasts were purchased from
American Type Culture Collection (Manassas, VA), and
were cultured and transfected with plasmids as described
previously by our lab [29]. Myotubes were treated on day
3 of differentiation with 10 ng/mL of IL-6 for either 0 or
3 hours prior to harvest and firefly/renilla luciferase activ-
ity was measured as previously described [29].
RNA isolation
RNA was extracted from TA and diaphragm muscles using
TRIzol as previously described [16]. Isolated total RNA was
subsequently purified using an RNeasy Mini kit (Qiagen,
Valencia, CA), according to manufacturer’s instructions.
The resulting quantity and purity of total RNA was tested
through absorbance spectrophotometry at 230, 260 and
280 nm, and the quality of RNA was tested on a 1% de-
naturing agarose gel. Synthesis of cDNA and qRT-PCR
analyses from RNA isolated from the TA and diaphragm
were performed as described previously [28] using a 7300
real-time PCR system and the following primers from
Applied Biosystems (Austin, TX): Fbxo30 (NM_027968.3),
Fbxo31 (NM_133765.4), Bach2 (NM_001109661.1), Socs3
(NM_007707.3), Ubr2 (NM_146078.3), Psma2 (NM_
008944.2), Ubqln1 (NM_026842.4), Fos (NM_010234.2),
Cebpb (NM_009883.3), Stat3 (NM_011486.4), Col6a2
(NM_146007.2), Myoz3 (NM_133363.3), atrogin-1/MAFbx/
Fbxo32 (NM_026346.2), MuRF1/Trim63 (NM_001039048.2),
Bcl3 (NM_033601.3), and Maff (NM_010755.3).Microarray
For microarray analysis, 16 total RNA samples from two
conditions (control and tumor bearing) transduced with
either AAV9-ev or AAV9-d.n.FoxO (4 samples per
group, 4 groups) were sent to the Boston University
Medical Center Microarray Core Facility for amplifica-
tion, labeling, and hybridization on the mouse Affyme-
trix Gene 1.0 ST array (Santa Clara, CA, USA). This
microarray is designed to measure the expression of
28,132 well-annotated genes. A total of sixteen array im-
ages were acquired by GeneChip Scanner 3000 TG and
the image (expression) quality was assessed by the Affy-
metrix Expression Console (Santa Clara, CA, USA). The
Expression File Creator module of the GenePattern plat-
form was used to generate gene expression signal values
[30] and were normalized by robust multi-array analysis
algorithm (RMA) [31]. Brainarray MoGene 1.0 ST cus-
tom Chip Definition File v.16 was used for probe anno-
tation [32]. The resulting expression data for 21,225
genes were uploaded for Principle Component Analysis
(PCA) on the Genepattern platform [30]. We found one
outlier from the AAV9-ev C26 group using PCA and
thus, this sample was removed from further analysis.
The expression values were log2-transformed and pre-
processed by the Pre-ProcessDataSet module of Gene-
Pattern to include genes with expression values between
1-220, a min.fold.change ≥ 2 and a min delta ≥ 1.2. The
last two variation filters were set to eliminate genes that
showed no expression change among the 15 samples but
to include genes showing changes at low expression
values. In the Pre-ProcessDataSet module, min.fold.
change is defined as the fold change of the 2nd highest
expression value among the 15 samples compared to the
2nd lowest value among the 15 samples, whereas min
delta is defined as the difference between the 2nd high-
est expression value and the 2nd lowest value among the
15 samples [30]. Both .cel files and expression values
were deposited into MIAME compliant NCBI Gene Ex-
pression Omnibus [33] with accession #GSE56555. Fol-
lowing these filtering and preprocessing steps, 20,432
genes remained.
Differential gene expression analyses were subsequently
performed using the Comparative Marker Selection mod-
ule in GenePattern [30], which compares mean differences
between two groups by two-way parametric t-tests. To
identify differentially expressed genes in muscles from
tumor-bearing mice, expression values from the AAV9-ev
control group were compared to the AAV9-ev C-26 group
(using q ≤ 0.01 and −1.5 ≥ fold change ≥1.5-fold), which
identified 2,194 genes. Then, to identify the direct or indir-
ect FoxO target genes during cancer, the differentially
expressed genes due to cancer were compared to expres-
sion values from the AAV9-d.n.FoxO C-26 group (q ≤ 0.01
and −1.5 ≥ fold change ≥1.5-fold), which identified 544
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AAV9-d.n.FoxO during control conditions (AAV9-ev con-
trol vs. AAV9-d.n.FoxO control, q < 0.01), were eliminated
as FoxO target genes in response to the C26 tumor.
Upregulated or downregulated FoxO target genes in re-
sponse to the C26 tumor were analyzed separately for
their associated functional annotations using the DAVID
Bioinformatics database [34]. Enriched terms and bio-
logical networks were identified using pre-selected default
annotation categories, an EASE score (a modified Fisher
Exact P-value) of less than 0.05 and an enrichment score
greater than 1.5. Enriched terms were clustered using the
Functional Annotation Clustering tool, which groups
analogous annotations together to reduce redundancy in
the report. FoxO target genes were also analyzed using the
Broad Institute’s Molecular Signatures Database [35] to
identify enriched canonical pathways and to identify the
most commonly shared transcription factor binding motifs
located within the -2 kb to 2 kb cis-regulatory regions of
these genes.
Statistical analyses
Methods used for statistical analysis of the microarray
data are described in the results section. All other data
were analyzed using ANOVA followed by Bonferroni
post hoc comparisons (GraphPad Software, San Diego,
CA) and significance was set at P ≤ 0.05.
Results
FoxO is necessary for locomotor and diaphragm wasting
in C26 tumor-bearing mice
Wasting of locomotor muscles is an important component
of whole body weakness and fatigue in cancer patients. In
addition, the diaphragm muscle also undergoes significant
wasting and is believed to play a key role in respiratory
complications and mortality in cancer patients. Despite
this, studies aimed at understanding the mechanisms of
muscle wasting during cancer have largely focused on loco-
motor muscles. Thus, in the current study we focused on
the role of the FoxO factors in cancer-induced wasting of
both locomotor muscles and the diaphragm in response to
Colon-26 tumor. To inhibit endogenous FoxO1, FoxO3a
and FoxO4 DNA binding-dependent transcription we
transduced muscles with recombinant AAV9-d.n.FoxO (or
AAV9-ev as the respective control) both of which also ex-
press GFP as a non-fusion protein to visualize transductionTable 1 Effect of AAV9-d.n.FoxO on muscle fiber CSA in C26 t
Control AAV9-ev Control AAV
TA fiber CSA 1489 μm2 ± 155 2065* μm2 ±
EDL fiber CSA 1518 μm2 ± 90 1705 μm2 ± 7
Diaphragm fiber CSA 1021 μm2 ± 91 1024 μm2 ± 8
*p < 0.05 vs control AAV9-ev group, †p < 0.05 vs. AAV9-ev C26 group. Data represenefficiency. Importantly, the d.n.FoxO sequence consists of
only that which codes for the FoxO3a DNA binding do-
main, and shares 85% sequence identity with the respective
DNA binding domain of FoxO1 and 75% sequence identity
with that of FoxO4 (Figure 1), all of which share >90%
sequence conservation within this region. The d.n.FoxO
therefore acts through outcompeting endogenous FoxO1,
FoxO3a and FoxO4 for binding to FoxO DNA binding ele-
ments, and, since it lacks a transactivation domain, blocks
FoxO DNA binding-dependent transcription. To transduce
locomotor muscles we performed a single intramuscular
injection of AAV9 into the TA and EDL muscles of mice.
To transduce the diaphragm, in a separate cohort of
animals we performed a single intrathoracic injection
of AAV9. Immediately following AAV9 injections, mice
assigned to the tumor-bearing groups were inoculated with
C26 cells, and control mice injected with 1×PBS. Muscles
from control and tumor-bearing mice were harvested at
tumor end point (~26 days post C26-inoculation) when
mice lose ~15% of their tumor-free body mass, which
has been documented by us previously [9]. Using these
methods, we were able to achieve nearly 100% AAV9
transduction efficiency of fibers in the TA muscle and the
diaphragm and ~75% transduction efficiency of fibers
in the EDL as visualized by GFP fluorescence in muscle
cross-sections (Figure 1).
As shown in Table 1 and Figure 2, presence of the C26
tumor induced significant muscle fiber atrophy in the TA,
EDL, and diaphragm of mice transduced with AAV9-ev.
In contrast, muscles of tumor-bearing mice transduced
with AAV9-d.n.FoxO showed significant sparing of muscle
fiber CSA. These data therefore demonstrate that blocking
FoxO-dependent transcription is sufficient to impede
C26-induced muscle wasting of both locomotor muscles
and the diaphragm, which extends previous findings that
FoxO is necessary for locomotor muscle wasting during
LLC- and S-180-induced cancer cachexia [17]. Notably,
transduction of muscles of non-tumor-bearing mice with
AAV9-d.n.FoxO significantly increased fiber CSA over the
26 day period in the TA as observed previously by our lab.
Increased fiber size was also observed in the EDL, but pre-
sumably due to the lower AAV9 transduction efficiency,
this did not reach statistical significance (p = 0.16) since all
fibers in muscle cross-sections were measured in order to
make sense of subsequent muscle force measurements in
the EDL. In contrast, fiber size was not altered by AAV9-umor-bearing mice
9-d.n.Foxo C26 AAV9-ev C26 AAV9-d.n.FoxO
94 1013* μm2 ± 76 1479† μm2 ± 94
5 716* μm2 ± 60 1106*† μm2 ± 57
2 696* μm2 ± 81 980† μm2 ± 50
t mean ± SE, n = 6 mice per group.
Figure 2 Inhibition of FoxO impedes C26-induced muscle fiber atrophy and weakness. (A-D) The average cross-sectional area of muscle
fibers in the TA (A), EDL (B) and diaphragm (C) of control or cachectic C26 mice transduced with AAV9-ev or AAV9-d.n.FoxO was calculated
following incubation of muscle cross-sections with Alexa Fluor-conjugated wheat germ agglutinin to label muscle fiber membranes. (D) Representative
diaphragm muscle cross-sections from each group. Data represent mean ± SE, n = at least 6 animals per group. (E-H) Maximum absolute tetanic force
(E), specific force (F), time to peak tension (G) and half-relaxation time (H) was calculated in EDL muscles from control or cachectic C26 mice transduced
with AAV9-ev or AAV9-d.n.FoxO. Data represent mean ± SE, n = 4 animals/group. *p < 0.05 vs AAV9-ev control group. †p < 0.05 vs. AAV9-ev C26 group.
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high transfection efficiency. Although it is unclear why
blocking FoxO induced hypertrophy of limb muscles, but
not the diaphragm, this differential regulation may be re-
lated to the distinct activity pattern and function of the dia-
phragm, which is constantly active to support breathing.
In order to determine whether the sparing of muscle
fiber size in muscles of C26 tumor-bearing mice trans-
duced with AAV9-d.n.FoxO carried over to sparing of
muscle force deficits, we also harvested a subset of EDL
muscles for measurement of in vitro contractile properties.The rationale for choosing the EDL (over the TA and dia-
phragm) for force measurements is due to two main rea-
sons: 1) the relatively small size of the EDL allows for
efficient diffusion of oxygen and nutrients necessary for
force measurements (which is not possible in the TA),
and; 2) the EDL contains tendons on both sides which al-
lows for both specific and maximal absolute force mea-
surements (maximal absolute force measurements are not
possible in the diaphragm). We found that EDL muscles
from C26 mice transduced with AAV9-ev showed a 40%
decrease in maximum absolute force and an 11% decrease
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trol mice transduced with AAV9-ev, both of which were
statistically significant (Figure 2E,F). In contrast, muscles
from tumor-bearing mice transduced with AAV9-d.n.
FoxO showed only a 28% decrease in maximum absolute
force and a 6% (non-significant) decrease in specific
muscle force, when compared to EDL muscles of control
mice transduced with AAV9-ev. Although the attenuation
of force deficits by AAV9-d.n.FoxO was not complete,
these data are comparable with the effect of AAV9-d.n.
FoxO on fiber size in EDL muscles of tumor-bearing mice,
in which we saw only a partial sparing of fiber CSA due to
the measurement of both transduced and non-transduced
muscle fibers. Thus, given that only ~75% of fibers were
transduced with AAV9-d.n.FoxO, it seems likely that a
greater attenuation of muscle weakness would have oc-
curred had we achieved a more complete transduction of
fibers within the EDL. Notably, EDL muscles from control
mice transduced with AAV9-d.n.FoxO over the 26 day
period showed a non-significant (p = 0.09) decrease in
maximum absolute muscle force when compared to
AAV9-ev control, which suggests that chronically blocking
FoxO in the absence of an atrophy stimulus may have a
negative impact on force generating capacity.
Further analysis of contractile properties of the EDL
demonstrated no significant differences in time to peak
tension in response to the C26 tumor or AAV9-d.n.FoxO
(Figure 2G). In contrast, half-relaxation time was signifi-
cantly slowed (elevated) in response to the C26 tumor,
which was completely prevented in muscles transduced
with AAV9-d.n.FoxO (Figure 2H). Collectively, these data
indicate that FoxO-dependent transcription is necessary
for C26-induced muscle atrophy of locomotor muscles
and the diaphragm, and that FoxO activation is also causa-
tive in C26-induced muscle contractile dysfunction.
Microarray analysis to identify direct or indirect FoxO
target genes during C26 cancer cachexia
To comprehensively identify the gene networks changed in
response to the C26 tumor which require FoxO-dependent
transcription, we harvested TA muscles from control and
cachectic C26 mice transduced with AAV9-ev or AAV9-d.
n.FoxO for microarray analysis. We identified 2,194 genes
that were differentially expressed between control and C26
mice injected with AAV9-ev (−1.5 ≥ fold change ≥ 1.5, q ≤
0.01). Subsequent comparison of these genes between C26
mice injected with either AAV9-ev or AAV9-d.n.FoxO
showed that 544 genes were differentially expressed in the
presence of AAV9-d.n.FoxO (q ≤ 0.01and fold change
≥1.5). Out of these genes, 1 gene (Ip6k3) was significantly
changed by AAV9-d.n.FoxO during control conditions
(q < 0.01) and was thus eliminated as a downstream target
of FoxO in response to the C26 tumor. Out of the
remaining 543 genes regulated via a FoxO-dependentmanner, 296 genes were upregulated in skeletal muscle
due to the C26 tumor (see Additional file 1) and 247 were
downregulated (see Additional file 2). To identify the
broader gene networks, biological processes and canonical
pathways regulated through FoxO in response to tumor
burden, we functionally categorized these genes using the
DAVID Bioinformatics database [34,36] and the Broad
Institute Molecular Signatures Database (MSigDB) [37].
Transcripts upregulated in response to the C26 tumor
were analyzed separately from transcripts downregulated
in response to the C26 tumor.
Transcription factors, including Cebpb and AP-1, are
downstream targets of FoxO in cachectic muscle
Among the 296 direct or indirect FoxO target genes up-
regulated in skeletal muscle of C26 tumor-bearing mice,
the most highly enriched biological annotation clusters
identified through DAVID were related to the Basic Leu-
cine Zipper (bZIP) transcription factors, the proteasome
complex, transcriptional regulation and apoptosis. Ranked
in order of significance, the most highly enriched annota-
tion term from each of the top 10 non-redundant annota-
tion clusters identified via DAVID are shown in Figure 3B
(top panel). The top 10 Broad MSigDB canonical path-
ways, ranked in order of significance, are also shown in
Figure 3B (bottom panel), which revealed findings consist-
ent with the DAVID analysis. Among the top 20 canonical
pathways, seven were related to protein degradation, in-
cluding metabolism of amino acids, the proteasome, and
antigen processing: ubiquitination and proteasome deg-
radation. An additional seven pathways were associated
with inflammatory processes, including AP-1, IL-6 and
apoptosis. Expression data for FoxO-regulated transcripts
belonging to enriched canonical pathways of interest are
shown in Table 2.
Among the FoxO-regulated genes annotated to the ca-
nonical IL-6 and/or AP-1 pathways are several bZIP tran-
scription factors including CCAAT/enhancer-binding
protein beta (Cebpb), and factors which heterodimerize
within the AP-1 transcription factor complex, including v-
fos FBJ murine osteosarcoma viral oncogene homolog
(Fos), Fosl2, Fosb and Jun B proto-oncogene (Junb). Based
on these findings we postulated that transcription factor
binding motifs for C/EBPβ and AP-1, in addition to FoxO,
would be enriched in the promoter regions of genes iden-
tified as indirect or direct targets of FoxO. Thus, in a sep-
arate analysis we used Broad’s Gene Set Enrichment
Analysis tool to analyze the -2 kb to 2 kb cis-regulatory re-
gions surrounding the transcriptional start site of upregu-
lated FoxO target genes to identify the most commonly
shared conserved transcription factor consensus motifs.
This tool uses overlap comparison of user-provided gene
lists and gene sets defined in the TRANSFAC (version 7.4)
database as those which share a cis-regulatory motif
Figure 3 (See legend on next page.)
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Figure 3 Genome-wide identification of gene networks regulated by FoxO in muscles of cachectic C26 tumor-bearing mice. (A) Microarray
analyses were performed on TA muscles from control and cachectic C26 mice transduced with either AAV9-ev or AAV9-d.n.FoxO. Comparison of
control and C26 AAV9-ev groups revealed 2,194 gene transcripts which were differentially expressed in response to C26 (FDR q-value < 0.01 and
fold-change≥ 1.5-fold). Of these genes, 543 genes were differentially regulated in muscles from C26 mice transduced with d.n.FoxO (AAV9-ev C26 vs.
AAV9-d.n.FoxO C26, FDR q-value < 0.01 and fold-change≥ 1.5-fold) and were thus considered as downstream targets (direct or indirect) of FoxO.
(B and C) Gene transcripts upregulated (B) or downregulated (C) in response to C26 which were identified as FoxO targets were analyzed using the
DAVID functional annotation clustering module and Broad’s Molecular Signature Database to identify enriched biological processes and Canonical
Pathways. The top 10 most highly enriched DAVID annotation clusters and MSigDB Canonical Pathways from each gene set are ranked in order of
significance and are plotted against the -log of the p-value. (D and E) Gene expression changes of select transcripts identified via microarray as
downstream targets of FoxO were validated using qRT-PCR analyses. Data represent mean ± SE, n = at least 3 animals/group. *p < 0.05 vs AAV9-ev
control group. †p < 0.05 vs. AAV9-ev C26 group.
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nomes. Due to the conservation of these motifs across
species, these sites are more likely to reflect putative gene
regulatory elements. As expected, a TTGTTT consensus
motif, which is annotated to FoxO4 (q = 3.76E-13), and is
part of the core FoxO consensus motif also regulated by
FoxO1 and FoxO3a, was identified as the second most
commonly shared motif (see Additional file 3: Table S1).
Moreover, although less commonly shared, the complete
reverse FoxO consensus motif (G/A)TAAACA (annotated
to FOXF2, q = 2.08E-06), which matches the FoxO DNA
binding element (FBE) regulated by FoxO1 and FoxO3a in
the MuRF1 promoter [38], was also significantly shared
among the genes in our dataset. In addition, as hypothe-
sized a motif corresponding to AP-1 (TGANTCA, q =
8.33E-12) was identified as the third most commonly
shared motif. Thus, although associative, these findings at
least support the notion that a subset of the genes identi-
fied as downstream targets of FoxO during cancer may be
related to FoxO-dependent regulation of AP-1 transcrip-
tion factors. Also among the top 10 most commonly
shared consensus motifs were two motifs annotated to
STAT5. Although the role of STAT5 in skeletal muscle
wasting is unknown, STAT3 binds to an analogous motif
and was recently shown to mediate muscle atrophy in
C26 tumor-bearing mice [11]. STAT3 is activated
through the IL-6 Pathway, which was also among the
top 10 canonical pathways regulated by FoxO in re-
sponse to tumor burden. Expression data for gene tran-
scripts regulated by FoxO that are annotated to the IL-6
pathway are shown in Table 2, which includes the bona
fide STAT3 target gene, suppressor of cytokine signaling
3 (Socs3).
Proteasome components enriched among FoxO targets
upregulated in cachectic muscle
Based on the analyses performed using both DAVID and
the MSigDB, genes involved in proteasomal protein degrad-
ation were enriched among the gene transcripts upre-
gulated in cachectic muscle through a FoxO-dependent
manner. Expression data for FoxO-regulated genes an-
notated to the “Proteasome” and “Antigen processing:ubiquitination and proteasome degradation” are shown in
Table 2. Included are genes that encode for various sub-
units of the 26S proteasome, including the 20S core (Psma2
and Psma7) and the 19S regulator (Psmc2, Psmc4, Psmd3
and Psmd4) which confers substrate specificity to the 26S
complex. Several additional genes which function as E3 li-
gases were also identified as downstream targets of FoxO,
including F-box/WD repeat-containing protein 11 (Fbx11),
Socs3, kelch-like ECH-associated protein 1 (Keap1), splA/
ryanodine receptor domain and SOCS box containing 1
(Spsb1) and F-box protein 31 (Fbxo31) (Table 2). In
addition, Cathepsin-L, Gabarapl1 and Bnip3, which are
known gene targets of FoxO in skeletal muscle involved
in protein degradation through the lysosomal/autoph-
agy pathway [39,40], were also identified as FoxO
targets during cancer. Atrogin-1/MAFbx (Fbxo32) and
MuRF1 (Trim63), although slightly repressed by d.n.FoxO,
did not pass the statistical criteria set for the identification
of FoxO-dependent targets in limb muscles of cachectic
mice (see Additional file 3: Table S2). This finding there-
fore suggests that in addition to FoxO, other factors likely
contribute to the transcriptional upregulation of atrogin-1
and MuRF1 during cancer cachexia, which has been re-
ported previously [13]. Alternatively, since the d.n.FoxO
construct inhibits FoxO-dependent transcription through
outcompeting endogenous FoxO for DNA binding, it is
also possible that endogenous FoxO factors could still
regulate atrogin-1 and MuRF1 transcription in the pres-
ence of d.n.FoxO through a DNA-binding independent
manner.
FoxO is necessary for cancer-induced downregulation of
genes encoding ECM and Z-disc proteins
In addition to the 296 FoxO target genes upregulated in
skeletal muscle of C26 tumor-bearing mice, FoxO was also
necessary for the C26-induced downregulation of 247
genes. Analysis of these genes using the Functional Cluster-
ing Tool within DAVID identified the Extracellular Matrix,
Leucine-Rich Repeats, the Z-disc and Glycosylation among
the most highly enriched annotations (Figure 3C, top
panel). Use of the Broad Molecular Signatures Database to
identify top canonical pathways from this gene set further
Table 2 Enriched gene networks upregulated via FoxO during cancer cachexia
MSigDB pathway C26 (Fold change)
1 2 3 4 5 6 Gene description Gene symbol AAV9-ev AAV9-dnFoxO*
x x x x proteasome subunit, alpha type, 7 Psma7 2.40 1.38
x x x x proteasome subunit, alpha type, 2 Psma2 2.95 1.73
x x x x proteasome 26S subunit, ATPase, 2 Psmc2 2.31 1.47
x x x x proteasome 26S subunit, ATPase, 4 Psmc4 2.47 1.49
x x x x proteasome 26S subunit, non-ATPase, 3 Psmd3 2.15 1.34
x x x x proteasome 26S subunit, non-ATPase, 4 Psmd4 2.67 1.69
x BCL2-like 11 (apoptosis facilitator) Bcl2l11 3.01 1.82
x x FBJ murine osteosarcoma oncogene Fos 16.75 5.70
x x jun B proto-oncogene Junb 5.40 2.48
x early growth response 1 Egr1 4.07 1.95
x matrix metallopeptidase 9 Mmp9 2.52 1.57
x FOS-like antigen 2 Fosl2 3.50 2.09
x angiotensinogen Agt 5.00 2.64
x FBJ murine osteosarcoma oncogene B Fosb 3.90 1.43
x x f-box and WD-40 domain protein 11 Fbxw11 1.88 1.15
x x murine thymoma viral oncogene homolog 1 Akt1 2.61 1.54
x x BCL2-like 1 Bcl2l1 3.01 1.82
x x suppressor of cytokine signaling 3 Socs3 6.63 3.08
x CCAAT/enhancer binding protein beta Cebpb 2.94 1.82
x kelch-like ECH-associated protein 1 Keap1 1.95 1.25
x splA/ryanodine receptor dom and SOCS box Spsb1 6.36 3.91
Other genes of interest
immediate early response 5 Ier5 3.46 1.74
immediate early response 3 Ier3 3.02 1.64
ubiquilin-1 Ubqln1 1.93 1.25
f-box protein 31 Fbxo31 3.25 1.79
BCL2/adenovirus E1B interacting protein 3 Bnip3 2.53 1.51
Cathepsin L Ctsl 3.07 1.79
GABA(A) receptor-associated protein like 1 Gabarapl1 4.44 2.52
Heme Oxygenase 1 Hmox1 5.91 1.68
Expression changes of FoxO target genes of interest belonging to enriched Molecular Signatures Database (MSigDB) Canonical Pathways are shown for C26
tumor-bearing groups transduced with AAV9-ev or AAV9-d.n.FoxO.
All data represent fold-change in response to the C26 tumor, normalized to the absolute control group (AAV9-ev control). *q<0.01 vs AAV-ev C26 group. MSigDB
Canonical Pathways: 1. Metabolism of Amino Acids and Derivatives, 2. AP-1, 3. Activation of NF-κB in B-cells, 4. Apoptosis, 5. IL-6, 6. Antigen Processing:
Ubiquitination and Protein Degradation.
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tions, focal adhesion, ECM organization and collagen for-
mation as the top canonical pathways (Figure 3C, bottom
panel). Expression changes of downregulated genes belong-
ing to enriched annotation categories of interest are shown
in Table 3. Several of these targets have previously been
documented via microarray analysis to be downregulated
in skeletal muscle of cachectic C26 tumor-bearing mice
[9,12], though this is the first evidence demonstrating the
requirement of FoxO for their downregulation. Included
among the genes downregulated in a FoxO-dependentmanner were those encoding for Type I and Type VI colla-
gens. As shown in Table 3, these collagens are part of sev-
eral ECM-related pathways, and play an important role in
maintaining the structural integrity of muscle during con-
traction. In addition, several small leucine-rich repeat pro-
teoglycans (SLRPs) were also identified as FoxO-regulated
transcripts downregulated in cachectic muscle, including
Chondroadherin, Keratocan, Osteoglycin, Asporin, Fibro-
modulin and Lumican. While the functions of these SLRPs
in skeletal muscle are not well understood, these proteins
are located in the ECM where they regulate the structure
Table 3 Enriched gene networks downregulated via FoxO during cancer cachexia
MSigDB pathway C26 (Fold change)
1 2 3 4 5 Gene description Gene symbol AAV9-ev AAV9-dnFoxO*
x x x x x collagen, type I, alpha 2 Col1a2 −4.26 −2.31
x x x x x collagen, type I, alpha 1 Col1a1 −5.20 −2.44
x x x x x collagen, type VI, alpha 1 Col6a1 −2.64 −1.70
x x x x x collagen, type VI, alpha 2 Col6a2 −2.69 −1.71
x x x x x collagen, type VI, alpha 3 Col6a3 −3.55 −1.75
x x x thrombospondin 2 Thbs2 −1.62 −1.07
x x x tenascin C (hexabrachion) Tnc −2.43 −1.45
x x integrin, beta 6 Itgb6 −10.24 −2.20
x x cartilage oligomeric matrix protein Comp −2.48 −1.05
x x chondroadherin Chad −16.34 −2.40
x fibrillin 1 Fbn1 −2.86 −1.71
x Rho-associated, coiled-coil protein kinase2 Rock2 −1.98 −1.16
x x collagen, type XIV, alpha 1 (undulin) Col14a1 −2.08 −1.26
x x procollagen C-endopeptidase enhancer Pcolce −1.81 −1.10
x matrix metallopeptidase 15 Mmp15 −3.12 −2.06
DAVID annotation
1 2 3 4 5
x x x myozenin 3 Myoz3 −5.53 −1.99
x x x integrin beta 1 binding protein 2 (melusin) Itgb1bp2 −4.25 −2.07
x x x junctophilin 2 Jph2 −3.95 −2.10
x x x synemin, intermediate filament protein Synm −2.61 −1.47
x x x homer homologue 1 Homer1 −2.26 −1.45
x x x LIM domain binding 3/Zasp/Cypher Ldb3 −1.84 −1.14
x x fibromodulin Fmod −3.29 −1.29
x x keratocan Kera −14.38 −3.30
x x lumican Lum −2.47 −1.43
Expression changes of FoxO target genes belonging to enriched Molecular Signatures Database (MSigDB) Canonical Pathways and DAVID functional annotation
categories of interest are shown for C26 tumor-bearing groups transduced with AAV9-ev or AAV9-d.n.FoxO.
All data represent fold-change in response to the C26 tumor, normalized to the absolute control group (AAV9-ev control). *q<0.01 vs AAV-ev C26 group. MSigDB
Canonical Pathways: 1. Extracellular Matrix (ECM) Receptor Interactions, 2. Integrin1 Pathway, 3. Focal Adhesion, 4. ECM Organization, 5. Collagen Formation.
DAVID Functional Annotations: 1. Z-disc, 2. I-band, 3. Sarcomere, 4. N-linked Glycosylation, 5. Small leucine-rich repeat proteoglycan.
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factor interactions with their cellular receptors [41]. Also
enriched among the downregulated transcripts regulated
downstream of FoxO were several genes whose protein
products localize to the muscle sarcomere, and in particu-
lar, the Z-disc (Table 3). Included among these are Cypher,
also known as ZASP or Limb domain binding protein 3
(Ldb3), Homer1 and Myozenin 3 (Myoz3, also known as
calsarcin-3), all of which play critical roles in muscle fiber
integrity and function [42-44]. Although the significance of
these ECM and Z-disc proteins during cancer cachexia is
unknown, the integrity of the sarcomere as well as the
muscle fiber membrane, which is tightly linked with the
ECM, is notably disrupted in cachectic muscle [6,45].
In order to gain insight into the mechanisms whereby
FoxO may contribute to gene downregulation duringcancer cachexia we used the Broad Institute’s Gene Set
Enrichment Analysis tool to identify common transcrip-
tion factor consensus motifs located within the promoter
regions of genes whose downregulation during cancer re-
quired FoxO. Among the top 10 most commonly shared
conserved transcription factors consensus motifs were
those corresponding to nuclear factor of activated T-cells
(NFAT), FOXO4, myocyte-specific enhancer factor 2A
(MEF2A), serum response factor (SRF), and myogenic dif-
ferentiation 1 (MyoD) (see Additional file 3: Table S3).
qRT-PCR validation of transcripts regulated by FoxO
To validate a subset of the transcripts identified via
microarray as downstream targets of FoxO during C26,
we performed qRT-PCR using cDNA generated from the
same RNA samples used in the microarrays. As shown
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array analysis, FoxO was necessary for the cancer-
induced upregulation of Cebpb, Fos, Fbxo31 and Psma2,
and was necessary for the cancer-induced downregula-
tion of Col6a2, Myoz3 and Tnc (interaction effect, p <
0.05, AAV9-ev C26 vs. AAV9-d.n.FoxO C26, p < 0.05).
In contrast, the levels of Cypher/Ldb3 were not statisti-
cally different between the AAV9-ev C26 vs. AAV9-d.n.
FoxO C26 groups.
FoxO-dependent gene transcripts in the diaphragm
during cancer cachexia
As shown in Table 1, inhibition of FoxO-dependent tran-
scription completely prevented diaphragm muscle fiber at-
rophy during C26-induced cachexia. Therefore, in order to
determine whether FoxO regulates similar gene targets in
the diaphragm as in the TA, we performed qRT-PCR ana-
lyses on diaphragm muscles. Included in these analyses
were also transcripts of interest that marginally missed the
fold-change and/or significance criteria to be classified as
FoxO-dependent transcripts in response to cancer in the
TA (see Additional file 3: Table S2). This included Stat3
and the ubiquitin E3 ligases atrogin-1/MAFbx, MuRF1,
Ubr2 and Fbxo30, the latter of which was recently identified
as a FoxO target gene necessary for denervation-induced
atrophy [46]. As shown in Figure 4A, similar to the TA, dia-
phragm muscles from C26 mice showed significant in-
creases in the gene transcripts of various genes involved in
protein degradation, including Socs3, Ubqln1, Psma2,
Fbxo31, Fbxo30, and Ubr2, all of which were significantly
repressed in diaphragm muscles of C26 mice transduced
with AAV9-d.n.FoxO. We also found, similar to the TA,
numerous transcription factor transcripts to be upregulated
in the diaphragm in response to C26, including the b-ZIP
transcription factors, Fos, Bach2 and Cebpb, as well as
Stat3 and Bcl3 (Figure 4B), each of which were significantly
repressed or abolished in diaphragm muscles transduced
with AAV9-d.n.FoxO. We also found that similar to the TA
muscle, in response to cancer diaphragm muscles showed
a significant downregulation of the collagen transcript,
Col6a2, and Myoz3, which encodes the Z-disc-associated
protein Myozenin 3, and that their downregulation was
blocked in muscles transduced with AAV9-d.n.FoxO
(Figure 4C). In addition, the C26-induced increase in
atrogin-1 (Fbxo32) and MuRF1 (Trim63) in the diaphragm
were significantly repressed by d.n.FoxO. This finding is in
contrast to the TA, where their repression by d.n.FoxO
did not reach statistical significance. This discrepancy
could be related to the increased sensitivity of qRT-PCR in
comparison to microarray. We therefore validated the ef-
fect of d.n.FoxO on the C26-induced increase in atrogin-1
and MuRF1 in TA muscles via qRT-PCR, and found a
greater magnitude of repression than indicated on
the microarray (~40% repression of atrogin-1, ~60%repression of MuRF1), both of which reached statistical
significance (p < 0.05, data not shown). However, since
the magnitude of repression by d.n.FoxO was still consid-
erably greater for both atrogin-1 and MuRF1 in the dia-
phragm than in the TA, these data suggest that
additional transcription factors perhaps more active in
limb muscle also play a role in atrogin-1 and MuRF1
transcription during cancer cachexia, which has been
reported previously [13].
FoxO1 and/or FoxO3a are sufficient to upregulate Fos,
Cebpb, and Stat3
The identification of Cebpb, Fos and Stat3 as downstream
targets (direct or indirect) of the FoxO factors during can-
cer cachexia is significant, as each of these transcription
factors have been identified to regulate the muscle atrophy
program. More specifically, Cebpb is necessary for muscle
wasting during LLC-induced cancer cachexia [13], Stat3
for muscle wasting during C26 cancer cachexia [11], and
Fos for denervation-induced muscle loss [47]. Moreover,
the heterodimeric AP-1 transcription factor containing c-
JUN, (which commonly dimerizes with FOS) is also neces-
sary for muscle wasting in AH-130 tumor-bearing rats,
which further implicates FOS in cancer-induced muscle
wasting [14]. To further establish the FoxO factors as up-
stream regulators of these atrophy-related transcription fac-
tors, we next determined whether FoxO1 and/or FoxO3a
were sufficient to increase the mRNA levels of Cebpb, Fos
and Stat3 in skeletal muscle. We also determined whether
FoxO1 and FoxO3a were sufficient to increase the expres-
sion of Socs3 and Ubr2, which are bona fide targets of
STAT3 and C/EBPβ, respectively. We therefore injected
and electroporated into skeletal muscle expression plas-
mids encoding “constitutively active” FoxO1 (FoxO1 TM)
or FoxO3a (FoxO3a TM) which are mutated at the three
Akt phosphorylation sites and harvested muscles 4 days
later for qRT-PCR analysis. As shown in Figure 4D, FoxO1
TM significantly increased the mRNA levels of Cebpb (3.8-
fold) and the C/EBPβ target gene, Ubr2 (3.9-fold). On the
other hand, FoxO3a TM significantly increased the mRNA
levels of Stat3 (1.4-fold), Fos (4.3-fold), Cebpb (3.1-fold)
and Ubr2 (3.8-fold), but not Socs3. Since both FoxO1 and
FoxO3a were sufficient to increase Cebpb mRNA to similar
magnitudes, we analyzed the Cebpb proximal promoter
and identified two potential Forkhead boxO binding ele-
ments (FBEs) within 300 base pairs upstream of the tran-
scription start site. A literature search revealed that FoxO1
binds to these sites within the Cebpb promoter to regulate
Cebpb transcription in adipocytes in response to TNFα
[25]. We therefore determined whether these FBEs within
the Cebpb promoter are also necessary for increased Cebpb
transcription in response to IL-6, a predominant cytokine
in the C26 model of cancer cachexia. To test this we trans-
fected C2C12 skeletal muscle cells with luciferase reporter
Figure 4 FoxO1 and FoxO3a regulate Cebpb, Fos and Stat3 gene expression. (A-C) Select transcripts identified via microarray as
downstream targets of FoxO in locomotor muscles during C26 cancer cachexia were validated as targets in the diaphragm via qRT-PCR analyses.
Data represent mean ± SE, n = 3–5 animals/group. *p < 0.05 vs AAV9-ev control group. †p < 0.05 vs. AAV9-ev C26 group. (D) FoxO1 TM or FoxO3a
TM expression plasmids were injected and electroporated into TA muscles of mice and harvested 4 days later for qRT-PCR analyses. Data represent
mean ± SE, n = 5 animals/group. *p < 0.05 vs empty vector (EV). (E) C2C12 myoblasts were transfected with a pRL-TK-Renilla reporter plus a WT Cebpb
promoter reporter construct or a Cebpb reporter construct which is mutated at two putative Forkhead binding elements, which prevents FoxO DNA
binding. Following 3 days of differentiation, myotubes were treated with IL-6 (10 ng/mL) for 3 hours and harvested for measurement of firefly/renilla
luciferase activity. Data represent mean ± SE, n = at least 9 wells/group. *p < 0.05 vs control. †p < 0.05 vs. WT Cebpb promoter.
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Cebpb proximal promoter (−516 to −1) or a mutated frag-
ment (mFBE1/2) which contains base pair substitutions at
both FBEs within the Cebpb promoter which prevent FoxODNA binding [25]. Following differentiation into myotubes
we treated cells with IL-6 for 3 hours and then harvested
cells for measurement of luciferase activity. As shown in
Figure 4E, treatment with IL-6 significantly increased
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FBEs.
Discussion
Muscle wasting during cancer is a unique and multifac-
torial process which likely involves the differential regu-
lation of multiple signaling pathways and downstream
targets that together promote the wasting phenotype.
However, the specific muscle proteins which mediate
these intracellular responses to tumor burden are only
beginning to be defined. In the current study we extend
recent findings that the FoxO transcription factors are
necessary for locomotor muscle fiber atrophy during
Lewis Lung carcinoma [16] and S-180 sarcoma [17] to
show that FoxO is required for skeletal muscle fiber at-
rophy in response to C26 adenocarcinoma in both loco-
motor muscles and the diaphragm, the primary muscle
required for inspiration. This is significant, since dia-
phragm wasting during cancer may link the degree of
cachexia with increased mortality. Importantly, through
performing the first genome-wide microarray analysis of
transcripts regulated in a FoxO-dependent manner in
skeletal muscle during cancer cachexia, we reveal several
gene networks changed in cachectic muscle that require
FoxO. Indeed, while the FoxO factors are well known to
regulate genes involved in protein degradation which
was confirmed through our study, we provide new evi-
dence that during cancer FoxO is also necessary for the
gene upregulation of various atrophy-related transcrip-
tion factors (and their associated transcriptional net-
works), including Cebpb, Stat3 and AP-1. In addition,
we further demonstrate that FoxO also plays a key role
in mediating the cancer-induced downregulation of vari-
ous genes which function in the maintenance of muscle
structural integrity. Collectively these findings highlight
FoxO as a critical factor controlling diverse transcriptional
networks in skeletal muscle during cancer cachexia, which
provides novel insight into additional mechanisms whereby
the FoxO transcription factors may orchestrate the muscle
atrophy phenotype.
Atrophy-related transcription factors identified as
downstream targets of FoxO in response to tumor
burden
Several transcription factors were identified through micro-
array analysis as downstream targets of FoxO in response
to tumor-burden, including the atrophy-related bZIP tran-
scription factors, Cebpb and Fos. The identification of
Cebpb as a downstream target of FoxO in skeletal muscle
during cancer is of particular interest, since the protein
expression of C/EBPβ is increased in muscles of tumor
bearing mice, and mice lacking C/EBPβ are resistant to
LLC cancer-induced muscle wasting [13]. Moreover, we
also found that both FoxO1 and FoxO3a are sufficient toincrease Cebpb mRNA in skeletal muscle. Although we
cannot ascertain, based on our findings, whether FoxO1 or
FoxO3a directly induce Cebpb gene transcription during
cancer cachexia, there are two putative FBEs located within
the Cebpb proximal promoter that FoxO1 has previously
been documented to bind [25]. Here we show that these
FBEs are necessary for Cebpb promoter activation in skel-
etal muscle in response to IL-6, a predominant cytokine in
the C26 model of cancer cachexia. Given the requirement
of C/EBPβ for cancer-induced muscle wasting, it seems
likely that FoxO-dependent upregulation of Cebpb plays a
role in the muscle wasting phenotype induced by FoxO
during cancer.
The significance of the immediate early gene and onco-
genic transcription factor, FOS, as a FoxO target in skel-
etal muscle during cancer cachexia is currently unknown.
However, Fos was the third most highly upregulated FoxO
target gene in response to C26 (16-fold), which is in align-
ment with a previous microarray study showing upregula-
tion of Fos in muscles from both moderately and severely
cachectic C26 tumor-bearing mice [12]. Importantly, Fos
is also upregulated in skeletal muscle following denerv-
ation and knockdown of Fos prevents the associated
muscle atrophy, thus highlighting its role in the atrophy
program [47]. Despite the unknown role of FOS in
cancer-induced wasting, FOS heterodimerizes with c-JUN
within the AP-1 transcription factor complex, which has
been established as a factor required for muscle wasting in
AH-130 tumor-bearing rats [14]. Since the AP-1 pathway
was identified as a top canonical pathway regulated by
FoxO in cachectic muscle, it seems logical that FoxO-
dependent induction of Fos could play a role in the enrich-
ment of this pathway. Notably, in addition to Fos we also
found that FoxO was necessary for the C26-induced in-
crease in other early response genes related to the AP-1
pathway, including immediate early response 5 (Ier5), and
early growth response 1 (Egr-1). Importantly, both Egr-1
and Ier5 were recently identified as cachexia-associated
genes upregulated in muscles of pancreatic cancer patients
together with Foxo1 [18]. Erg-1 was increased greater than
60-fold in patients exhibiting cachexia compared to non-
cachectic cancer patients, and is considered a master regu-
lator of inflammatory response. To our knowledge these
findings are the first to link FoxO to the regulation the
AP-1 pathway during cancer cachexia which represents a
potentially novel role for FoxO in mediating the wasting
phenotype during cancer.
FoxO regulates proteolytic genes in skeletal muscle in
response to tumor burden
Many of the upregulated genes identified as downstream
targets of FoxO in muscles of C26 tumor-bearing mice are
involved in protein degradation, and are coordinately up-
regulated during multiple wasting conditions [48-50].
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and Ubiquilin-1 (Ubqln1) which encodes for an ubiquitin-
like (UBL) protein which physically interacts with both
proteasomes and ubiquitin ligases and is involved in pro-
tein degradation [51]. In addition, several genes whose
protein products function in ubiquitin E3 ligase complexes
were also identified as downstream targets of FoxO, in-
cluding Socs3, Fbxw11, Keap1, Spsb1 and Fbxo31. While
little is known about the substrates and functions of these
E3 ligases in skeletal muscle, Fbxw11 (also known as
β-TrCP2) plays a role in targeting IκBα for ubiquitin-
dependent degradation [52]. This finding is intriguing,
since the degradation of IκBα is necessary for muscle
wasting during cancer [7,9,10]. Importantly, FoxO is well-
established to regulate proteolysis during wasting condi-
tions [39,40,53], and we confirmed several known FoxO
targets involved in proteolysis as dependent targets of FoxO
during cancer. Included among these were autophagy-
related target genes (Bnip3, Cathepsin-L and Gabarapl1),
as well as Fbxo30/MUSA1, which was recently reported as
a novel FoxO target gene which encodes an ubiquitin E3
ligase that is required for denervation-induced muscle loss
[46]. Thus, based on these findings, it is reasonable to
speculate that FoxO-dependent upregulation of these genes
involved in proteolysis through both the ubiquitin prote-
asome pathway and the lysosomal/autophagy pathway
likely plays an important role in cancer-induced wasting.FoxO is necessary for ECM and sarcomere gene
downregulation in response to tumor burden
Unexpectedly, nearly half of the genes regulated by FoxO
during cancer were downregulated in response to the C26
tumor. While FoxO could mediate gene repression through
direct binding to gene promoters, as has been documented
previously [54-56], FoxO may also regulate gene repression
through indirect mechanisms. This is suggested by the pro-
moter analyses performed on downregulated target genes
which identified enrichment of conserved binding motifs
for not only FoxO, but several transcription factors that
regulate muscle gene products, including NFAT, MEF2,
and MyoD. Thus, FoxO could indirectly contribute to gene
repression through inhibiting the activity of these and other
transcription factors. One mechanism whereby FoxO
could mediate this is through increasing the expression of
transcriptional repressors and co-repressors. In fact, in-
hibitor of DNA-binding/differentiation proteins 1 (Id1)
and 3 (Id3), which act as transcriptional repressors of
myogenic basic helix-loop-helix (bHLH) proteins such as
MyoD [57], were both identified as downstream targets of
FoxO increased in cachectic muscle. The direct and indir-
ect mechanisms whereby FoxO contributes to gene re-
pression during cancer thus warrant further investigation,
and will be important in moving this work forward.A significant number of the downregulated FoxO targets
during cancer encode for proteins that localize to the ECM
and the Z-disc of the muscle sarcomere. Despite the rela-
tively long half-life of typical structural proteins, prolonged
downregulation of these transcripts over several weeks or
even months during the progression of cancer should logic-
ally be sufficient to decrease protein expression. Provided
this holds true for even a small subset of the downregulated
targets, the impact of their downregulation could be highly
significant to the progression of cancer-induced wasting
and weakness. Indeed, many of the target genes downregu-
lated via FoxO play critical roles in maintaining muscle in-
tegrity, fiber size and contractile function. Just one example,
the extracellular matrix protein, Tenascin C (Tnc), is in-
creased in response to muscle damage, exerts anabolic and
proliferative effects on interstitial and myogenic cells, and
intriguingly, its genetic ablation is sufficient to decrease
muscle mass, cause selective atrophy of type II muscle fi-
bers, and slow muscle contractile properties [58]. Since
these phenotypes are also characteristic of muscle wasting
during cancer, it is intriguing to speculate that the down-
regulation of Tnc could play a role in these pathologies.
Strikingly, many of the ECM-related FoxO target genes
downregulated in cachectic muscle of C26 tumor-bearing
mice, including the collagen VI encoding genes, are pre-
dominately expressed and secreted by interstitial fibroblasts
[59]. Indeed, fibroblasts and other stromal cells are the pri-
mary cells responsible for synthesizing the ECM and the col-
lagen network. Although the effect of cancer on the muscle
ECM and collagen network are not well defined, fibroblast
activation protein-α (FAP)-positive stromal cells are signifi-
cantly reduced in skeletal muscles of C26 tumor-bearing
mice and depletion of these cells is sufficient to induce
muscle fiber atrophy [60]. Moreover, collagen VI produced
from muscle fibroblasts is critical to the structural integrity
and function of the muscle and is also an important compo-
nent of the satellite cell niche, that is necessary for satellite
cell self-renewal and muscle regeneration [61]. In addition
to repressing the expression of several collagen transcripts,
we also found that FoxO was necessary for the coordinate
increase in the gene expression of matrix metalloproteinase
8 (Mmp8) and Mmp9 in muscles of cachectic tumor-
bearing mice (Table 2 and Additional file 3: Table S1), which
participate in the degradation of Type I, II and III collagens
and Type IV collagens, respectively. Therefore, determining
whether the ECM and collagen network are disrupted in
skeletal muscle during cancer cachexia, and whether this is
mediated through a FoxO-dependent manner, warrants fur-
ther investigation. Moreover, since we know that fibroblasts
are the predominant source of collagen and other ECM
components identified as downstream targets of FoxO dur-
ing cancer, determining the role of the FoxO factors in regu-
lating muscle fibroblasts as it relates to cancer cachexia also
warrants further study.
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In summary, the current study identifies FoxO as a crit-
ical factor required for muscle wasting in locomotor
muscles and the diaphragm in response to C26 cancer
cachexia. Moreover, these findings provide new evidence
that FoxO-dependent transcription is a central node
controlling diverse gene networks in skeletal muscle dur-
ing cancer cachexia which may act coordinately to regu-
late the atrophy phenotype. Indeed, our findings indicate
that FoxO regulates not only genes involved in proteoly-
sis, but also acts as an upstream regulator of several
transcriptional networks, including C/EBPβ and the AP-
1 and IL-6 pathways. Intriguingly, our findings also indi-
cate that FoxO plays a critical role in the cancer-induced
downregulation of genes involved in ECM and sarco-
mere structure, which suggests an entirely novel role for
FoxO in regulating muscle integrity during cancer. The
data presented in this study thus highlights several novel
candidate genes and biological networks that are tar-
geted by FoxO that may be further explored as causative
factors in cancer-induced muscle wasting.Additional files
Additional file 1: List of FoxO target genes upregulated in skeletal
muscle during C26 cancer cachexia.
Additional file 2: List of FoxO target genes downregulated in
skeletal muscle during C26 cancer cachexia.
Additional file 3: Tables S1, S2 and S3. Enriched transcription factor
binding motifs in promoter regions of FoxO target genes upregulated
(Table S1) and downregulated (Table S3) during C26 cancer cachexia.
Table S2. Expression data for additional gene transcripts of interest.
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